92 related articles for article (PubMed ID: 8623490)
1. A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.
Johnson EM; Zimmerman J; Duderstadt K; Chambers J; Sorenson AL; Granger DK; Almond PS; Fryer Jp; Leventhal JR; Scarola J; Matas AJ; Canafax DM
Transplant Proc; 1996 Apr; 28(2):987. PubMed ID: 8623490
[No Abstract] [Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.
Brattström C; Tydén G; Säwe J; Herlenius G; Claesson K; Groth CG
Transplant Proc; 1996 Apr; 28(2):985-6. PubMed ID: 8623489
[No Abstract] [Full Text] [Related]
3. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis.
Tejani A; Alexander S; Ettenger R; Lerner G; Zimmerman J; Kohaut E; Briscoe DM
Pediatr Transplant; 2004 Apr; 8(2):151-60. PubMed ID: 15049795
[TBL] [Abstract][Full Text] [Related]
4. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients.
Brattström C; Säwe J; Tydén G; Herlenius G; Claesson K; Zimmerman J; Groth CG
Ther Drug Monit; 1997 Aug; 19(4):397-406. PubMed ID: 9263380
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
Kahan BD; Karlix JL; Ferguson RM; Leichtman AB; Mulgaonkar S; Gonwa TA; Skerjanec A; Schmouder RL; Chodoff L
Transplantation; 2003 Oct; 76(7):1079-84. PubMed ID: 14557756
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
[TBL] [Abstract][Full Text] [Related]
7. Combined rapamycin and cyclosporine immunosuppression in a porcine renal transplant model.
Granger DK; Cromwell JW; Canafax DM; Matas AJ
Transplant Proc; 1996 Apr; 28(2):984. PubMed ID: 8623488
[No Abstract] [Full Text] [Related]
8. Pharmacokinetics of rapamycin.
Yatscoff RW
Transplant Proc; 1996 Apr; 28(2):970-3. PubMed ID: 8623483
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus: a new agent for clinical renal transplantation.
Kahan BD
Transplant Proc; 1997; 29(1-2):48-50. PubMed ID: 9123092
[No Abstract] [Full Text] [Related]
10. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent.
Kaplan B; Meier-Kriesche HU; Napoli KL; Kahan BD
Clin Pharmacol Ther; 1998 Jan; 63(1):48-53. PubMed ID: 9465841
[TBL] [Abstract][Full Text] [Related]
11. Concentration-controlled immunosuppressive regimens using cyclosporine with sirolimus or brequinar in human renal transplantation.
Kahan BD
Transplant Proc; 1995 Feb; 27(1):33-6. PubMed ID: 7879019
[No Abstract] [Full Text] [Related]
12. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
Levy G; Schmidli H; Punch J; Tuttle-Newhall E; Mayer D; Neuhaus P; Samuel D; Nashan B; Klempnauer J; Langnas A; Calmus Y; Rogiers X; Abecassis M; Freeman R; Sloof M; Roberts J; Fischer L
Liver Transpl; 2006 Nov; 12(11):1640-8. PubMed ID: 16598777
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration.
Zimmerman JJ; Kahan BD
J Clin Pharmacol; 1997 May; 37(5):405-15. PubMed ID: 9156373
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of sirolimus in kidney transplant patients.
Ferron GM; Mishina EV; Zimmerman JJ; Jusko WJ
Clin Pharmacol Ther; 1997 Apr; 61(4):416-28. PubMed ID: 9129559
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.
Budde K; Neumayer HH; Lehne G; Winkler M; Hauser IA; Lison A; Fritsche L; Soulillou JP; Fauchald P; Dantal J;
Nephrol Dial Transplant; 2004 Oct; 19(10):2606-14. PubMed ID: 15316094
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants.
Jusko WJ; Ferron GM; Mis SM; Kahan BD; Zimmerman JJ
J Clin Pharmacol; 1996 Dec; 36(12):1100-6. PubMed ID: 9013365
[TBL] [Abstract][Full Text] [Related]
17. Beneficial metabolic impact of the novel immunosuppressant rapamycin in chronic canine islet autograft recipients.
Kneteman NM; Lakey JR; Wagner T; Finegood D
Transplant Proc; 1995 Dec; 27(6):3213. PubMed ID: 8539919
[No Abstract] [Full Text] [Related]
18. Role of therapeutic drug monitoring of rapamycin.
Kahan BD; Napoli KL
Transplant Proc; 1998 Aug; 30(5):2189-91. PubMed ID: 9723436
[No Abstract] [Full Text] [Related]
19. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients.
Budde K; Lehne G; Winkler M; Renders L; Lison A; Fritsche L; Soulillou JP; Fauchald P; Neumayer HH; Dantal J;
J Clin Pharmacol; 2005 Jul; 45(7):781-91. PubMed ID: 15951468
[TBL] [Abstract][Full Text] [Related]
20. Clinical safety and tolerability of microemulsion cyclosporine in stable renal transplant patients.
Gracida C; Melchor JL
Transplant Proc; 1996 Dec; 28(6):3379. PubMed ID: 8962318
[No Abstract] [Full Text] [Related]
[Next] [New Search]
